10-K: Range Impact, Inc. Reports Significant Losses in 2024, Navigating Strategic Shift

Range Impact, Inc. faced a challenging 2024, marked by a net loss of $9.8 million and strategic realignments including asset sales and discontinued operations.

Summary

• Range Impact, Inc. reported a net loss of $9,798,083 for the year ended December 31, 2024.
• The company used $1,591,426 of cash in operating activities during the same period.
• Revenues decreased significantly to $9,011,081 in 2024 from $19,346,306 in 2023.
• The company sold substantially all assets of Collins Building and its drug development assets (Graphium Biosciences) during 2024.
• Goodwill was fully impaired, resulting in a $751,421 charge against earnings.
• The company is actively seeking additional financing to fund operations.
• There is substantial doubt about the company's ability to continue as a going concern within one year of the date that the financial statements are issued.
• As of March 28, 2025, the company employed 18 full-time employees.
• The company has five operating business segments: Range Reclaim, Range Minerals, Range Water, Range Security, and Range Land.

Sentiment

Score: 3

Explanation: The document presents a largely negative outlook due to significant losses, declining revenue, and concerns about the company's ability to continue as a going concern. While the company is seeking financing, the overall tone is cautious.

Positives

• The company is actively seeking additional financing and other sources of capital to fund its currently estimated level of operations.
• The company has established a cybersecurity policy designed with a comprehensive framework for identifying, assessing, mitigating, and responding to cybersecurity risks across the organization.

Negatives

• The company incurred a net loss of $9,798,083 for the year ended December 31, 2024.
• The company used $1,591,426 of cash in operating activities during the same period.
• Revenues decreased significantly to $9,011,081 in 2024 from $19,346,306 in 2023.
• The company sold substantially all assets of Collins Building and its drug development assets (Graphium Biosciences) during 2024.
• Goodwill was fully impaired, resulting in a $751,421 charge against earnings.
• The company's cash balance as of December 31, 2024, was $167,286.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing and achieving profitable operations.
• The company may not have sufficient funds to operate its business for the next 12 months.
• The company faces competition from larger and better-capitalized entities.
• The company's impact investing strategy is new and untested.
• The company's financial results depend on successful project execution and may be adversely affected by cost overruns.
• The company is subject to environmental-related claims, which could result in significant costs and time to comply.
• The company depends on a limited number of customers for a significant portion of its revenues.

Future Outlook

The company is actively seeking additional financing and other sources of capital to fund its currently estimated level of operations and is managing working capital to generate additional cash flow.

Industry Context

The company operates in the impact investing space, focusing on environmental and social solutions in economically disadvantaged regions, particularly Appalachia. The company faces competition from various operating businesses and investment funds.

Comparison to Industry Standards

• The document does not contain sufficient information to make a detailed comparison to industry standards.
• Comparable companies in the environmental services and impact investing sectors include Casella Waste Systems, Covanta Holding Corporation, and Republic Services, Inc.
• However, a direct comparison is difficult due to the unique focus and scale of Range Impact, Inc.

Management Changes

Related Party Transactions

• The Company sold all of its common stock of Graphium Biosciences to a newly-formed entity, Placer Biosciences, Inc. (Placer), owned by two former officers of the Company, in exchange for a warrant to purchase 1,000 shares of Placers common stock (then representing 25% of the outstanding shares of Placer) at $0.01 per share and cash proceeds of $100.
• On January 21, 2025, the Company entered into a securities purchase agreement with Tower IV, LLC, an Ohio limited liability company (Tower IV), providing for the issuance and sale by the Company to Tower IV of an aggregate of 3,333,333 shares of the Company’s common stock (the Shares) at a price of $0.15 per share. The aggregate gross proceeds from the sale of the Shares are approximately $500,000. Mr. Joseph E. LoConti is the beneficial owner of Tower IV.

Stakeholder Impact

• Shareholders face potential dilution and a decline in stock value.
• Employees may face uncertainty due to the company's financial instability.
• Customers may be concerned about the company's ability to fulfill its obligations.
• Creditors face increased risk of non-payment.

Next Steps

• The company is actively seeking additional financing.
• The company is managing its working capital to generate additional cash flow.
• The company intends to discontinue the Range Minerals operating business segment beginning in 2025.

Key Dates

Keywords

reclamation, impact investing, environmental services, mine sites, Range Impact, financial results, going concern, Appalachia